TITLE

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C

AUTHOR(S)
Yoshida, H.; R.Tateishi; Arakawa, Y.; Sata, M.; Fujiyama, S.; Nishiguchi, S.; Ishibashi, H.; Yamada, G.; Yokosuka, O.; Shiratori, Y.; Omata, M.
PUB. DATE
March 2004
SOURCE
Gut;Mar2004, Vol. 53 Issue 3, p425
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: An increase in the incidence of hepatocellular carcinoma (HCC) in Japan since the 1980s suggests an imminent outbreak in other countries where viral spread occurred more recently. Interferon therapy for chronic hepatitis C, in general, has been shown to prevent HCC. Aims: To determine the scale of benefit in individual patients. Subjects: Histologically proven chronic hepatitis C patients in the Inhibition of Hepatocarcinogenesis by Interferon Therapy (IHIT) cohort (Ann Intern Med 1 999;131 :174), as updated in March 2003. Methods: The lifetime risk for HCC was calculated based on HCC incidence rates, stratified by sex, age, fibrosis stage, and outcome of interferon therapy. The gain in HCC free survival was defined as the difference between expected HCC free survival with sustained virological response and that without. Results: The gain in HCC free survival was greater when a patient was younger and fibrosis was more advanced. For example, a 30 year old male with F3 fibrosis gained 12.4 years by attaining sustained response while a patient with F1 fibrosis older than 60 years gained less than one year. For a treatment protocol with a given sustained response rate, prior estimation of the gain can be obtained by multiplying the calculated HCC free survival for responders by the response rate. Conclusions: The gain in HCC free survival may serve as an indicator of the benefit of interferon therapy in terms of HCC prevention and be useful in the consideration of indication and selection of treatment protocol for individual patients.
ACCESSION #
13492624

 

Related Articles

  • High Dose Interferon α--2b Therapy for Chronic Hepatitis C: An Open Label Study of the Response and Predictors of Response. Bellary, Somashekhar; Smith, David G.; Bankes, Patricia; Harris, Arthur; Shayiq, Rass; Black, Martin // American Journal of Gastroenterology;Feb1995, Vol. 90 Issue 2, p259 

    Objectives: The current recommended dose of interferon (IFN) for chronic hepatitis C is 3 million units (m.u.) 3 times a wk for 6 months, although the optimal dose is uncertain. In an open label cohort format, we evaluated the response rate at 6 months, the relapse rate at 12 months, the...

  • Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon a-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Siebert, Uwe; Sroczynski, Gaby; Wasem, Jürgen; Greiner, Wolfgang; Ravens-Sieberer, Ulrike; Aidelsburger, Pamela; Kurth, Bärbel; Bullinger, Monika; Schulenburg, J.-Matthias; Wong, John; Rossol, Siegbert // European Journal of Health Economics;Jun2005, Vol. 6 Issue 2, p112 

    The objective of this study was to translate and apply a decision-analytic model for chronic hepatitis C (CHC) to the German health care context using competence network collaboration. The German Hepatitis C Model (GEHMO) competence network used a systematic multistep approach to identify and...

  • Efficacy of interferon therapy for aged patients with chronic hepatitis C. Arase, Yasuji; Kumada, Hiromitsu // Journal of Gastroenterology;2004, Vol. 39 Issue 11, p1123 

    The article reports on the efficacy of interferon therapy for aged patients with chronic hepatitis C. Chronic hepatitis C infection can be associated with progressive liver disease that may evolve insidiously into liver cirrhosis and carriers an increased risk of hepatocellular carcinoma (HCC)....

  • Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. Roche, Bruno; Coilly, Audrey; Roque-Afonso, Anne-Marie; Samuel, Didier // Viruses (1999-4915);2015, Vol. 7 Issue 9, p5155 

    Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries. All patients who undergo LT with detectable serum HCV RNA experience graft reinfection progressing to cirrhosis within five years in...

  • A Little Shot Will Do Ya. McCashland, T. M. // American Journal of Gastroenterology;Jan2001, Vol. 96 Issue 1, p5 

    Provides information on the study "Interferon Beta Prevents Recurrence of Hepatocellular Carcinoma After Complete Resection or Ablation of the Primary Tumor--A Prospective Randomized Study of Hepatitis C Virus-Related Liver Cancer," by K. Ikeda, Y. Arase, S. Saitoh et al.

  • Risk of Hepatocellular Carcinoma and Secondary Structure of Hepatitis C Virus (HCV) NS3 Protein Amino-Terminus, in Patients Infected with HCV Subtype 1b. Nishise, Yuko; Saito, Takafumi; Sugahara, Kazuhiko; Ito, Jun-Itsu; Saito, Koji; Togashi, Hitoshi; Nagano-Fujii, Motoko; Hotta, Hak; Kawata, Sumio // Journal of Infectious Diseases;10/1/2007, Vol. 196 Issue 7, p1006 

    We conducted a retrospective study of 65 patients with chronic hepatitis C, to determine whether the secondary structure of the amino-terminal 120 residues of the hepatitis C virus (HCV) NS3 protein is associated with an increased risk of development of hepatocellular carcinoma (HCC). The...

  • A Controlled Study to Determine the Optimal Dose Regimen of Interferon-α 2b in Chronic Hepatitis C. Hakozaki, Yukiya; Shirahama, Tatsuoki; Katou, Masashi; Nakagawa, Katsuya; Oba, Kenichi; Mitamura, Keiji // American Journal of Gastroenterology;Aug1995, Vol. 90 Issue 8, p1246 

    Objectives: The efficacy of three different dose treatments of interferon (IFN) was evaluated in patients with chronic hepatitis C (HCV). Methods: Ninety-one patients with chronic hepatitis C were allocated to receive 3, 6, or 10 U of recombinant IFN-α 2b three times weekly for 24 wk. The...

  • Effect of Daily Administration Period of Natural α-Interferon in Patients with Chronic Hepatitis C. Toyoda, Hidenori; Nakano, Satoshi; Kumada, Takashi; Takeda, Isao; Sugiyama, Keiichi; Osada, Toshimasa; Kiriyama, Seiki // American Journal of Gastroenterology;Apr1996, Vol. 91 Issue 4, p743 

    Objective: A randomized, controlled trial was performed to study the effect of the period of daily administration of interferon therapy in patients with chronic hepatitis C. Patients and Methods: Sixty-three patients were administered a total dose of 480 MU of natural α-interferon, 6 MU each...

  • Hepatitis C virus: evasion of the interferon-induced antiviral response. Taylor, Deborah R. // Journal of Molecular Medicine;Jun2000, Vol. 78 Issue 4, p182 

    Hepatitis C virus (HCV) is an emerging virus of great medical significance. A low drug-response rate and a high frequency of persistent infection have caused HCV to reach pandemic proportions. Many infected individuals go on to develop liver cirrhosis and hepatocellular carcinoma, and HCV is now...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics